

PRESS RELEASE

ZINZINO

Corporate ID no. 556733-1045

FAO: News Editor

Gothenburg 2019-03-07

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2019

STRONG SALES GROWTH DURING FEBRUARY; ZINZINO BASED REVENUE INCREASED 21% AND THE TOTAL GROUP REVENUE WITH 18% COMPARED WITH THE PREVIOUS YEAR.

The revenue for Zinzino's sales markets increased by 21% to SEK 50.1 (41.4) million due to strong growth in several regions. Higher share of internal production during the month meant that Faun Pharma's external sales decreased by 22% and amounted to SEK 2.9 (3.7) million. Overall, the Group increased revenues by 18% to SEK 53.0 (45.1) million compared with the previous year.

Accumulated revenues for January-February increased with 16% to 106,5 (91,9) MSEK compared with the previous year.

Revenues distributed as follows:

Regions MSEK	Febr-19	Febr-18	Change	YTD 2019	YTD 2018	Change
Nordic Countries	29.8	31.2	-4%	60.7	61.7	-2%
Baltic States	4.7	3.6	29%	9.0	7.3	23%
Rest of Europa	13.6	5.1	168%	26.6	9.4	182%
North America	2.0	1.5	29%	3.7	3.2	16%
Zinzino	50.1	41.4	21%	100.0	81.6	23%
Faun Pharma	2.9	3.7	-22%	6.5	10.3	-37%
Zinzino Group	53.0	45.1	18%	106.5	91.9	16%

For more information please contact:

Dag Bergheim Pettersen, CEO Zinzino, Mobile: +47 (0) 93 22 57 00
www.zinzino.com

Pictures for free publication:

Marcus Tollbom, Mobile: +46 (0) 70 190 03 12

Certified Adviser:

Erik Penser Bank Aktiebolag: +46 (0)8 463 83 00 Email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 12:00 the 7th of March, 2019.

Zinzino AB (publ.) is a direct sales company that operates throughout Europe and North America. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has more than 120 employees and currently trades in 33 markets across Europe and North America. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, and in Florida, USA. Zinzino is a public company and its shares are listed on Nasdaq First North. In 2016, Zinzino was recognized with the award "Superföretag 2015" by Veckans Affärer and the "Gazelle" award by Dagens Industri.